123 related articles for article (PubMed ID: 29432567)
1. Bile Acid Sequestration by Cholestyramine Mitigates FGFR4 Inhibition-Induced ALT Elevation.
Schadt HS; Wolf A; Mahl JA; Wuersch K; Couttet P; Schwald M; Fischer A; Lienard M; Emotte C; Teng CH; Skuba E; Richardson TA; Manenti L; Weiss A; Graus Porta D; Fairhurst RA; Kullak-Ublick GA; Chibout SD; Pognan F; Kluwe W; Kinyamu-Akunda J
Toxicol Sci; 2018 May; 163(1):265-278. PubMed ID: 29432567
[TBL] [Abstract][Full Text] [Related]
2. A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.
Chan SL; Schuler M; Kang YK; Yen CJ; Edeline J; Choo SP; Lin CC; Okusaka T; Weiss KH; Macarulla T; Cattan S; Blanc JF; Lee KH; Maur M; Pant S; Kudo M; Assenat E; Zhu AX; Yau T; Lim HY; Bruix J; Geier A; Guillén-Ponce C; Fasolo A; Finn RS; Fan J; Vogel A; Qin S; Riester M; Katsanou V; Chaudhari M; Kakizume T; Gu Y; Porta DG; Myers A; Delord JP
J Exp Clin Cancer Res; 2022 Jun; 41(1):189. PubMed ID: 35655320
[TBL] [Abstract][Full Text] [Related]
3. FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
Weiss A; Adler F; Buhles A; Stamm C; Fairhurst RA; Kiffe M; Sterker D; Centeleghe M; Wartmann M; Kinyamu-Akunda J; Schadt HS; Couttet P; Wolf A; Wang Y; Barzaghi-Rinaudo P; Murakami M; Kauffmann A; Knoepfel T; Buschmann N; Leblanc C; Mah R; Furet P; Blank J; Hofmann F; Sellers WR; Graus Porta D
Mol Cancer Ther; 2019 Dec; 18(12):2194-2206. PubMed ID: 31409633
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity.
Bartz R; Fukuchi K; Ohtsuka T; Lange T; Gruner K; Watanabe I; Hayashi S; Oda Y; Kawaida R; Komori H; Kashimoto Y; Wirtz P; Mayer JA; Redondo-Müller M; Saito S; Takahashi M; Hanzawa H; Imai E; Martinez A; Hanai M; Häussinger D; Chapman RW; Agatsuma T; Bange J; Abraham R
Mol Cancer Ther; 2019 Oct; 18(10):1832-1843. PubMed ID: 31350344
[TBL] [Abstract][Full Text] [Related]
5. Asynchronous rhythms of circulating conjugated and unconjugated bile acids in the modulation of human metabolism.
Al-Khaifi A; Straniero S; Voronova V; Chernikova D; Sokolov V; Kumar C; Angelin B; Rudling M
J Intern Med; 2018 Nov; 284(5):546-559. PubMed ID: 29964306
[TBL] [Abstract][Full Text] [Related]
6. Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4.
Zhou Z; Chen X; Fu Y; Zhang Y; Dai S; Li J; Chen L; Xu G; Chen Z; Chen Y
Chem Commun (Camb); 2019 May; 55(42):5890-5893. PubMed ID: 31041948
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.
Fairhurst RA; Knoepfel T; Buschmann N; Leblanc C; Mah R; Todorov M; Nimsgern P; Ripoche S; Niklaus M; Warin N; Luu VH; Madoerin M; Wirth J; Graus-Porta D; Weiss A; Kiffe M; Wartmann M; Kinyamu-Akunda J; Sterker D; Stamm C; Adler F; Buhles A; Schadt H; Couttet P; Blank J; Galuba I; Trappe J; Voshol J; Ostermann N; Zou C; Berghausen J; Del Rio Espinola A; Jahnke W; Furet P
J Med Chem; 2020 Nov; 63(21):12542-12573. PubMed ID: 32930584
[TBL] [Abstract][Full Text] [Related]
8. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
Mellor HR
Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
[TBL] [Abstract][Full Text] [Related]
9. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man.
Lundåsen T; Gälman C; Angelin B; Rudling M
J Intern Med; 2006 Dec; 260(6):530-6. PubMed ID: 17116003
[TBL] [Abstract][Full Text] [Related]
10. Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model-Informed Dose Selection in Oncology First-in-Human Study: A Case of Roblitinib (FGF401).
Wilbaux M; Yang S; Jullion A; Demanse D; Porta DG; Myers A; Meille C; Gu Y
Clin Pharmacol Ther; 2022 Dec; 112(6):1329-1339. PubMed ID: 36131557
[TBL] [Abstract][Full Text] [Related]
11. FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma.
Huynh H; Prawira A; Le TBU; Vu TC; Hao HX; Huang A; Wang Y; Porta DG
Exp Mol Med; 2020 Nov; 52(11):1857-1868. PubMed ID: 33235319
[TBL] [Abstract][Full Text] [Related]
12. Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids.
Yu C; Wang F; Jin C; Huang X; McKeehan WL
J Biol Chem; 2005 May; 280(18):17707-14. PubMed ID: 15750181
[TBL] [Abstract][Full Text] [Related]
13. First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors.
Harding JJ; Jungels C; Machiels JP; Smith DC; Walker C; Ji T; Jiang P; Li X; Asatiani E; Van Cutsem E; Abou-Alfa GK
Target Oncol; 2023 Mar; 18(2):181-193. PubMed ID: 36787089
[TBL] [Abstract][Full Text] [Related]
14. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
15. An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers.
Al-Khaifi A; Rudling M; Angelin B
Gastroenterology; 2018 Oct; 155(4):1012-1016. PubMed ID: 29928896
[TBL] [Abstract][Full Text] [Related]
16. Alternate pathways of bile acid synthesis in the cholesterol 7alpha-hydroxylase knockout mouse are not upregulated by either cholesterol or cholestyramine feeding.
Schwarz M; Russell DW; Dietschy JM; Turley SD
J Lipid Res; 2001 Oct; 42(10):1594-603. PubMed ID: 11590215
[TBL] [Abstract][Full Text] [Related]
17. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways.
Wu AL; Coulter S; Liddle C; Wong A; Eastham-Anderson J; French DM; Peterson AS; Sonoda J
PLoS One; 2011 Mar; 6(3):e17868. PubMed ID: 21437243
[TBL] [Abstract][Full Text] [Related]
18. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4.
Yu C; Wang F; Kan M; Jin C; Jones RB; Weinstein M; Deng CX; McKeehan WL
J Biol Chem; 2000 May; 275(20):15482-9. PubMed ID: 10809780
[TBL] [Abstract][Full Text] [Related]
19. Dose-response of five bile acids on serum and liver bile Acid concentrations and hepatotoxicty in mice.
Song P; Zhang Y; Klaassen CD
Toxicol Sci; 2011 Oct; 123(2):359-67. PubMed ID: 21747115
[TBL] [Abstract][Full Text] [Related]
20. Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine.
Singhal R; Harrill AH; Menguy-Vacheron F; Jayyosi Z; Benzerdjeb H; Watkins PB
BMC Pharmacol Toxicol; 2014 Aug; 15():42. PubMed ID: 25086653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]